Nanoparticles Help to Enhance Lung Cancer PD-L1 Inhibitors - AZoNano

A nanoparticle-based immunotherapy, called ARAC (Antigen Release Agent and Checkpoint Inhibitor) enhanced the efficacy of PD-L1 inhibitors against lung cancer.

PD-L1 and PD-1 are immune checkpoints that control signal pathways associated with T-cell activation. Previously, scientists targeted the PD-1/PD-L1 axis with immune checkpoint inhibitors (ICIs) in p… [+6624 chars]

full article...